Comparing Adriamycin vs Atezolizumab
| Adriamycin (doxorubicin) | Atezolizumab |
|
|---|
| Adriamycin (doxorubicin) | Atezolizumab |
|
|---|---|---|
|
Prescription only
Prescribed for Breast Cancer, Bladder Cancer, Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Bronchogenic Carcinoma, Cancer, Diffuse Large B-Cell Lymphoma, Hodgkin's Lymphoma, Lymphoma... View more |
Prescription only
Prescribed for Hepatocellular Carcinoma, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Bladder Cancer, Alveolar Soft Part Sarcoma, Breast Cancer, Melanoma, Urothelial Carcinoma. Atezolizumab... View more |
Related suggestions Breast Cancer
Bladder Cancer
|
| More about Adriamycin (doxorubicin) | More about Atezolizumab | |
| Ratings & Reviews | ||
|
Adriamycin has an average rating of 4.8 out of 10 from a total of 5 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 40% reported a negative effect. |
Atezolizumab has an average rating of 7.2 out of 10 from a total of 6 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 17% reported a negative effect. |
|
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||
|
View all Adriamycin side effects |
View all Atezolizumab side effects |
|
| Drug Class | ||
| Generic Availability | ||
|
N/A |
N/A |
|
| Pricing and Coupons * Prices are without insurance | ||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
| Dosage Forms | ||
|
N/A |
|
| Brand Names | ||
|
N/A |
Tecentriq | |
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||
|
30 hours |
648 hours |
|
| CSA Schedule 1 View glossary of CSA terms | ||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
| Pregnancy Category | ||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
|
| Drug Interactions | ||
|
A total of 612 drugs are known to interact with Adriamycin:
|
A total of 627 drugs are known to interact with Atezolizumab:
|
|
| Alcohol/Food/Lifestyle Interactions | ||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
| Disease Interactions | ||
| First Approval Date | ||
|
N/A |
N/A |
|
| WADA Class View classifications | ||
|
N/A |
N/A |
|
| More Information | ||
| Patient Resources | ||
| Professional Resources | ||
| Related Treatment Guide | ||
|
||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.